Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays

Yusheng Qu., Robert Kirby., Richard Davies., Ayesha Jinat., Stefano Stabilini., Bin Wu., Longchuan Yu., BaoXi Gao., and Hugo M. Vargas. (2023). Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in Human Ether-a-Go-Go-Related Gene Assays. Nucleic Acid Therapeutics. Nucleic Acid Therapeutics, 2022.

This publication was awarded the '2024 Technology Innovation Publication Award' by the Safety Pharmacology Society.


View
Recommended Publications
Latest Publications
Beyond Hybridisation: Biologically Meaningful Protein Interactions of Oligonucleotides

Nature Communications paper ‘The nucleobase guanine at the 3′-terminus of oligonucleotide RGLS4326 drives off-target AMPAR inhibition and CNS toxicity'

The state of the art in secondary pharmacology and its impact on the safety of new medicines

Jenkinson, Steve Advanced In Vitro Screening of New Drugs for Proarrhythmic Activity, Genetic Engineering News. 2024 44:5, 48-50

View All
Action Potential Waveform Analysis in Human iPSC-Cardiomyocytes Enables Mechanistic Assessment of Multichannel Cardiac Effects
Beyond Hybridisation: Biologically Meaningful Protein Interactions of Oligonucleotides
View All
Metrion is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
Copyright © 2024 Metrion. All rights reserved | Privacy notice | Registered as a company in England and Wales: 09669815 | VAT: GB 219828479
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram